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AbstrAct
Accurate assessment of neuroblastoma outcome prediction remains challenging. 
Therefore, this study aims at establishing novel prognostic tumor DNA methylation 
biomarkers. In total, 396 low- and high-risk primary tumors were analyzed, of which 
87 were profiled using methyl-CpG-binding domain (MBD) sequencing for differential 
methylation analysis between prognostic patient groups. Subsequently, methylation-
specific PCR (MSP) assays were developed for 78 top-ranking differentially methylated 
regions and tested on two independent cohorts of 132 and 177 samples, respectively. 
Further, a new statistical framework was used to identify a robust set of MSP assays 
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IntroductIon
Neuroblastoma (NB), a childhood tumor that 
originates from precursor cells of the sympathetic nervous 
system, is a heterogeneous disease with prognosis 
ranging from excellent long-term survival to high-
risk with fatal outcome. In order to determine the most 
appropriate treatment modalities for each patient, patients 
are stratified into risk groups at the time of diagnosis, 
based on combinations of clinical (age of the patient, 
stage of the tumor) and biological (MYCN amplification 
status, DNA index, histopathology) parameters [1]. Use 
of this risk classification system has shown that patients 
characterized by the same clinicobiological parameters can 
have different disease outcomes, indicating that accurate 
assessment of prognosis of NB patients still remains 
difficult [2-4]. Therefore, additional prognostic markers 
are warranted, allowing a more accurate risk estimation 
and more rapid identification of those patients who will 
not benefit from current treatments. 
Molecular alterations of the epigenome, especially 
DNA methylation, have emerged as alternative targets 
of biomarker research. DNA methylation biomarkers 
potentially have great clinical value due to the stable 
nature of DNA. For this reason, there are many relevant 
applications of DNA methylation biomarkers in cancer. 
For example, they could be used for early tumor detection, 
tumor classification, stratification of treatment, tumor 
recurrence and patient prognosis, as well as predicting 
and monitoring a patient’s response to treatment (detailed 
review in reference [5]). In NB, several prognostic 
single-gene methylation biomarkers have been reported, 
e.g. promoter methylation of TNFRSF10D, CASP8, 
ZMYND10, RASSF1A, KRT19, GNAS, HIST1H3C, RB1 
and TDGF1 [6-11]. Furthermore, a CpG island methylator 
phenotype (CIMP), described as the aberrant and 
concordant methylation of multiple promoter CpG islands, 
has been shown to be of prognostic significance [12-16]. 
In this study, we aim to assess the primary NB 
tumor methylome in a genome-wide manner to identify 
differentially methylated regions (DMRs) between the 
prognostic patient groups, and to use these DMRs to 
establish and validate new and valuable biomarkers. 
results
Methyl-cpG-binding domain (Mbd) sequencing 
of primary tumors prioritizes differentially 
methylated regions (dMrs) between patient 
subgroups
The study design is schematically represented in 
Figure 1. In the discovery phase, two independent cohorts 
of 42 (MBD cohort I) and 45 (MBD cohort II) primary 
NB tumors, selected for risk classification and survival 
(low-risk survivors (LR-SURV), high-risk survivors 
(HR-SURV) and high-risk deceased (HR-DOD)), were 
analyzed by methyl-CpG-binding domain (MBD) 
sequencing (Supplemental Table 1A and B). Sheared 
input DNA was enriched towards methylated fragments 
using the high affinity of the MBD of the MeCP2 protein 
towards methylated cytosines. These methylation-enriched 
fractions, as well as the input (non-MBD-enriched) 
DNA of MBD cohort II were then further studied by 
next-generation sequencing. After raw data analyses, 
differentially methylated regions (DMRs) between patient 
subgroups were detected using DESeq, which uses count 
data as input. The following patient subgroups were 
compared: HR-SURV versus HR-DOD (on the entire 
cohorts, as well as on the high-risk MYCN amplified (HR-
MYCN1) and non-amplified (HR-MYCN0) cohorts only), 
LR-SURV versus HR-DOD, and HR-MYCN0 versus HR-
MYCN1 (Supplemental Table 2). The same analyses were 
performed on the input sample data in order to estimate 
the background signal and exclude falsely identified 
DMRs. The DESeq analyses yield for each region of 
of which the methylation score (i.e. the percentage of methylated assays) allows 
accurate outcome prediction. Survival analyses were performed on the individual 
target level, as well as on the combined multimarker signature. As a result of the 
differential DNA methylation assessment by MBD sequencing, 58 of the 78 MSP 
assays were designed in regions previously unexplored in neuroblastoma, and 36 
are located in non-promoter or non-coding regions. In total, 5 individual MSP assays 
(located in CCDC177, NXPH1, lnc-MRPL3-2, lnc-TREX1-1 and one on a region from 
chromosome 8 with no further annotation) predict event-free survival and 4 additional 
assays (located in SPRED3, TNFAIP2, NPM2 and CYYR1) also predict overall survival. 
Furthermore, a robust 58-marker methylation signature predicting overall and event-
free survival was established. In conclusion, this study encompasses the largest DNA 
methylation biomarker study in neuroblastoma so far. We identified and independently 
validated several novel prognostic biomarkers, as well as a prognostic 58-marker 
methylation signature. 
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interest the mean normalized counts per patient group, as 
well as the log2FoldChange and p-value for the statistical 
significance of the difference. By calculating the π-value 
(π = -ln pval * log2 fold change [17]) for each of these 
regions, a new significance score was defined, which 
was then used to rank the candidate prognostic DMRs. 
Hierarchical cluster analysis using normalized counts 
of the top-ranking DMRs yielded two sample clusters 
which mainly correspond to the patient groups used in 
the differential methylation analysis, highlighting the 
capability of our MBD sequencing analysis strategy in 
identifying biomarker candidates (examples shown in 
Supplemental Figure 1).
Methylation-specific PCR (MSP) assays are 
designed and tested on two independent cohorts
MBD sequencing data of the top-ranking DMRs 
(promoter regions and 5 kb windows) from the different 
prognostic comparisons were visualized in the Integrative 
Genomics Viewer (IGV; [18]) in order to locate the most 
informative (discriminative) region for MSP primer design 
(Figure 1). The importance of this step is illustrated by 
the promoter region of HNRNPH1, which was identified 
as differentially methylated between HR-SURV and HR-
DOD patients, and LR-SURV and HR-DOD patients 
(Supplemental Figure 2). MBD regions for which no clear 
discriminative region could be identified were excluded 
from further analyses and only DMRs hypermethylated 
in HR-DOD or HR-MYCN1 samples were considered for 
further evaluation. In total, 78 MSP assays (Supplemental 
Table 2) were designed, analytically validated and tested 
on 19 NB cell lines (Supplemental Table 3), positive and 
negative controls (the (in vitro methylated) HCT-116 
DKO cell line), along with two independent cohorts of 
148 (MSP cohort I) and 202 (MSP cohort II) primary NB 
samples assigned to one of the three defined prognostic 
patient groups (Supplemental Table 4). Also the ACTB 
Figure 1: schematic representation of the study design. Differentially methylated regions (DMRs) between the prognostic patient 
groups are identified by methyl-CpG-binding (MBD) sequencing on MBD cohort I and II. For the top candidate prognostic DMRs, the 
MBD sequencing data were visualized in order to locate the most informative region for methylation-specific PCR (MSP) assay design. 
These assays were subsequently tested on MSP cohort I and II. By applying specific methylation calling criteria [10], a binary dataset 
for each of these cohorts was constructed, which was subsequently used for survival analyses. Cq: quantification cycle, Tm: melting 
temperature; Sz: size; h: height. The subscript pos refers to the data of the positive control sample.
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primer pair, a control assay that does not contain CpG 
sites and thus should always generate a PCR product, 
was tested on these samples to confirm successful DNA 
preparation (bisulfite treatment and amplification). In 
total, 16 samples of MSP cohort I and 25 samples of MSP 
cohort II failed for this assay, probably due to low DNA 
quality, and were therefore excluded from the study. 
MSP confirms the validity of MBD sequencing in 
identifying candidate methylation biomarkers 
In both MSP cohort I and II, primary tumor samples 
of HR-DOD and HR-MYCN1 patients show more 
methylation events compared to either survivors (p = 
0.001 for both cohorts; Supplemental Figure 3A and 3B) 
and HR-MYCN0 patients (p < 0.001 for both cohorts; 
Supplemental Figure 3C and 3D), respectively. This 
again confirms the validity of MBD sequencing data in 
identifying candidate markers, as all MSP assays were 
designed in regions identified in the MBD sequencing 
data as being hypermethylated in HR-DOD or HR-
MYCN1 patients. To further strengthen MBD sequencing 
as a powerful technology for identification of genome-
wide differential methylation, the genomic locations of 
the in-house designed MSP assays were compared to the 
genomic locations of the cytosines interrogated on the 
Infinium HumanMethylation450 BeadChip Kit (HM450 
Figure 2: A new statistical framework was developed to identify a robust multimarker signature for accurate outcome 
prediction. The framework consists of three major steps: (1) signatures construction, (2) evaluation of the performance and robustness 
of the constructed signatures and (3) the selection of the final signature. Details of every step are described in the Materials and Methods 
section. a: assay; s: sample; TPR: true positive rate (sensitivity); TNR: true negative rate (specificity); balanced accuracy (BAC). 
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array; Illumina). Of note, 58 MSP assays (74.36%) do 
not overlap with an interrogated cytosine on the HM450 
array, and would thus not have been identified using this 
array technology (e.g. promoter region of UHRF2 in 
Supplemental Figure 4). Also, 36 MSP assays (46.15%) 
are located in non-promoter or non-coding regions.
Survival analyses on the individual MSP assay 
level identify new prognostic biomarkers
Overall, the percentage of methylated samples per 
MSP assay ranges from 96.97% to 2.27% in MSP cohort I, 
and from 97.18% to 1.70% in MSP cohort II, and variable 
percentages between the prognostic patient groups are 
detected (Supplemental Table 4). The results of the 
survival analyses (log-rank test) on each individual MSP 
assay and the different patient (sub)cohorts are indicated 
in Supplemental Table 2. Although the survival analyses 
on the high-risk subgroups did not yield significant results, 
analyses on the entire cohorts identified 9 individual 
prognostic MSP assays for overall survival (OS) and 5 
assays for event-free survival (EFS) that were significantly 
detected in both MSP cohort I and II (Table 1). For EFS, 
these assays are located in the promoter region or gene 
body of CCDC177 and NXPH1, and the long non-coding 
RNAs lnc-MRPL3-2 and lnc-TREX1-1. The additional 
prognostic assays for OS are located in the promoter 
Figure 3: A robust 58-marker methylation signature and methylation score of 25% predicts overall and event-free 
survival. Kaplan-Meier curves and log-rank p-values for overall survival (MSP cohort I in A. and MSP cohort II in B.) and event-free 
survival (MSP cohort I in C. and MSP cohort II in D.) are shown. The numbers of patients at methylation low- and high-risk as predicted 
by the 58-marker signature are indicated. The numbers in parentheses in the plots refer to the number of patients that experienced an event 
(death of disease for overall survival, and relapse, progression or death of disease for event-free survival). *Missing follow-up time for two 
methylation low-risk patients and three methylation high-risk patients. **Missing follow-up time for five methylation high-risk patients, 
and event status and follow-up time for one patient.
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region of SPRED3, TNFAIP2, NPM2 and CYYR1. For 
MSP assay011, which has prognostic value for both OS 
and EFS, the amplicon is located on chr8:143 498 349 - 
143 498 469 (flanking genes are TSNARE1 (downstream 
on ± 14 kb) and BAI1 (upstream on ± 47 kb on opposite 
strand)). The corresponding results of the univariable 
logistic regression analyses are also shown in Table 1, and 
associations between the prognostic DNA methylation 
biomarkers and established prognostic NB risk factors 
(MYCN amplification, age at diagnosis (both 12 and 18 
month cutoff) and International Neuroblastoma Staging 
System (INSS) stage [19]) are shown in Table 2. 
A 58-marker methylation signature with 
accompanying methylation score cutoff of 25% 
predicts overall and event-free survival
As all MSP assays were designed in regions 
identified as hypermethylated in HR-DOD or HR-MYCN1 
samples and as the MSP data show association with 
outcome (Supplemental Figure 3A-3D), the possibility of 
establishing a robust and accurate multimarker signature 
for OS and EFS based on the number of methylation 
events was explored. To this purpose, a new statistical 
framework was developed, which allows identification of 
a robust set of MSP assays of which the methylation scores 
(i.e. the percentage of methylated assays in each sample) 
allow accurate outcome prediction (details in Materials 
and Methods and Figure 2). The signature was trained on 
MSP cohort I and tested on MSP cohort II. For the high-
risk subgroups, the resulting signature was not prognostic, 
but using the entire sample cohorts, a set of 58 MSP 
assays (Supplemental Table 4) with a methylation score 
cutoff of 25% was put forward and shown to significantly 
predict OS (p < 0.001 for both cohorts, log-rank test) and 
EFS (p = 0.001 for MSP cohort I and p < 0.001 for MSP 
cohort II). For MSP cohort I, OS at 5 years of follow-up is 
80.14% (95% confidence interval (CI) 72.06 - 89.11) for 
the group of patients at methylation low-risk, compared 
to 47.74% (34.43 - 66.18) for the group of patients at 
methylation high-risk. The 5-year EFS is 80.54% (72.40 
- 89.61) and 55.22% (40.92 - 74.51) in the methylation 
low- and high-risk groups, respectively. For MSP cohort 
II, OS at 5 years of follow-up is 86.67% (79.92 - 93.98) 
for the methylation low-risk group, compared to 44.20% 
(34.14 - 57.23) for the methylation high-risk group. Here, 
the 5-year EFS is 86.86% (79.86 - 94.47) and 53.34% 
(42.06 - 67.65) in the methylation low- and high-risk 
groups, respectively. The corresponding Kaplan-Meier 
curves are depicted in Figure 3. Power analyses using 
these survival rates illustrate that the MSP cohorts contain 
sufficient numbers of samples to obtain 90% power at 5% 
significance level. The signature has a balanced accuracy 
(BAC) of 70.12% for OS and 65.71% for EFS on MSP 
cohort I. On MSP cohort II, these values are 71.28% and 
67.97%, respectively. Univariable logistic regression 
analyses also illustrate that the signature predicts OS and 
EFS, and multivariable logistic regression analyses show 
that the signature is a significantly independent predictor 
of OS in MSP cohort II after controlling for known risk 
factors (Supplemental Table 5). Associations between the 
signature predictions and established NB risk factors are 
Table 1: Survival analyses on the individual MSP assay level identify new biomarkers for overall and event-free 
survival.
Note. For each individual MSP assay, the log-rank p-values, and the p-value, odds ratio (OR) and 95% confidence interval 
(CI) of the univariable logistic regression analyses are shown. Methylation of the individual markers is associated with worse 
overall and event-free survival.
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shown in Table 3.
dIscussIon
MYCN amplification was identified as first genetic 
prognostic marker, in addition to age at diagnosis and 
tumor stage, which is still used today in therapeutic 
stratification [1]. Further studies have attempted to 
explore additional parameters to improve prognostic 
classification. Most notably, these include large 
chromosomal imbalances as well as transcriptome-based 
gene signatures. Given the low mutation burden, more 
recent sequencing efforts did not deliver significant novel 
tools for prognostic stratification [20], although ALK 
mutation status is of importance for including patients 
for targeted therapy with ALK inhibitors. Recent studies 
have shown that NB biology is also strongly determined 
by the epigenetic profile of the tumor, which has paved the 
way for prognostic DNA methylation biomarker research. 
During the past years, multiple prognostic single-gene 
methylation biomarkers have been described in NB; also 
a so-called CpG island methylator phenotype (CIMP) was 
found to be of prognostic value [6-16]. Here, we studied 
the NB methylome in a genome-wide manner to establish 
and validate novel prognostic biomarkers for OS and EFS. 
Several features contribute to the novel and 
comprehensive aspect of our study. A first important 
feature is the number of analyzed tumor samples. In total, 
396 primary tumors were included, which is the largest 
series studied to date. Most reported studies only rely on 
NB cell lines or on a relatively limited number of tumors 
in the discovery phase and thus fall short in covering the 
NB heterogeneity, or lack independent validation on large 
sample cohorts. Of note, previous studies on mRNAs 
and microRNAs in NB have emphasized that biomarkers 
are of little or no utility if they are not validated on 
an independent patient cohort [21,22]. Here, MBD 
sequencing was applied to 87 primary tumors, carefully 
selected for risk classification, allowing optimal biomarker 
discovery, and two independent cohorts of 132 and 177 
primary tumors were used to test the selected candidate 
Table 2: The nine individual prognostic MSP assays are differentially methylated between patient groups with distinct 
neuroblastoma risk factors.
Note. For each of the nine individual prognostic MSP assays the number (percentage) of methylated samples in each stratum 
of MSP cohort I and II is given. P-values are according to the Fisher’s exact test. INSS: International Neuroblastoma Staging 
System; MYCN0: MYCN non-amplified; MYCN1: MYCN amplified.
Oncotarget1967www.impactjournals.com/oncotarget
biomarkers. Power analyses further emphasize that these 
large sample collections result in adequate power of the 
study. 
Another important feature is that we made use of 
MBD sequencing of primary NB tumors in the discovery 
phase to identify novel biomarker candidates. Compared 
to the Illumina methylation arrays, which were previously 
applied to NB tumors, MBD sequencing interrogates more 
CpGs (approximately 18% of all CpGs versus < 2% for 
the arrays [23]) and thus allows extension of the biomarker 
discovery phase to previously unexplored regions. MBD 
sequencing also has higher genomic coverage than 
methodologies based on antibodies (methylated DNA 
immunoprecipitation (MeDIP)) [24]. This genome-wide 
assessment of the DNA methylation pattern is reflected 
in the final selection of MSP assays, as we have shown 
that most of the assays would not have been identified 
using the HM450 array and that a substantial part of the 
assays is located in non-promoter or non-coding regions. 
These findings support previous studies in other cancer 
types that show that it is important to extend the search 
for potentially clinical applicable DNA methylation 
biomarker to the entire methylome rather than focussing 
on promoter CpG islands of which methylation is in most 
cases inversely correlated to their transcriptional activity 
[5]. 
The prognostic relevance of the selected candidate 
biomarkers was further analyzed in two large independent 
cohorts using our previously established high-throughput 
and semi-automated MSP pipeline [10]. As these cohorts 
include a considerable number of both high-risk survivors 
and non-survivors, the candidates could not only be 
tested on the entire sample cohorts, but also on the high-
risk cohorts only. This analysis is very valuable, for the 
reason that the need for prognostic biomarkers is the 
highest within this group of patients. However, although 
differential methylation analyses and hierarchical 
clustering on the MBD sequencing data illustrate that 
high-risk survivors and high-risk non-survivors show 
different methylation patterns, the MSP screens did not 
table 3: the 58-marker signature predictions are associated with established neuroblastoma risk factors.
Note. For both OS and EFS, the number (percentages) of methylation high-risk samples in each stratum of MSP cohort I and 
II is given. All associations are statistically significant (p < 0.001; Fisher’s exact test). OS: overall survival; EFS: event-free 
survival; INSS: International Neuroblastoma Staging System; MYCN0: MYCN non-amplified; MYCN1: MYCN amplified. 
*Missing event-free survival status for one patient.
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identify markers that were significantly prognostic in both 
MSP high-risk cohort I and II. Importantly, this does not 
mean that high-risk DNA methylation biomarkers cannot 
be found. It only indicates that the methylation differences 
in the DMRs (of 2 kb or 5 kb) in the MBD sequencing data 
between these high-risk groups are too subtle to be easily 
translated in an MSP assay which only interrogates a few 
CpGs. Therefore, the possibility of establishing high-risk 
methylation biomarkers based on genome-wide bisulfite 
sequencing, which allows analysis of the methylome at the 
single CpG level, should be addressed in the future. These 
future studies might also benefit from focussing on more 
homogeneous high-risk patient groups, for example by 
only studying MYCN amplified or non-amplified samples, 
as the heterogeneity within our high-risk cohort might also 
have counteracted the possibility of establishing high-risk 
DNA methylation biomarkers. 
Nevertheless, our validation efforts allowed 
robust identification of prognostic assays on the entire 
patient cohorts. Newly discovered individual prognostic 
methylation biomarkers for event-free survival (EFS) are 
CCDC177 and NXPH1, and SPRED3, TNFAIP2, NPM2 
and CYYR1 for overall survival (OS). Interestingly, some 
of these biomarkers are linked with neuronal processes 
and/or have already been described in other tumor types. 
For example, NXPH1 encodes the neurexophilin 1 protein 
that forms a very tight complex with alpha neurexins, a 
group of proteins that promote adhesion between dendrites 
and axons, and methylation of this gene was previously 
described as potential diagnostic biomarker for breast 
cancer [26]. TNFAIP2 (tumor necrosis factor, alpha-
induced protein 2) was also found to be hypermethylated 
in colorectal cancer [27] and NPM2 (nucleophosmin/
nucleoplasmin 2) in melanoma [28] and acute myeloid 
leukemia [29]. Alterations of sequence and expression 
of CYYR1 (cysteine/tyrosine-rich 1) were previously 
observed in neuroendocrine tumors [30]. Remarkably, 
also three non-coding methylation biomarkers for OS and 
EFS were identified (lnc-MRPL3-2, lnc-TREX1-1 and 
assay011). Assay011 is located on chr8:143 498 349 - 143 
498 469, but further annotation is not available for this 
region. These findings again underscore the importance of 
screening the entire methylome for biomarker discovery. 
Of note, the role of methylation of these non-promoter 
CpGs in NB is currently unclear and should also be 
topic of further investigation, as it has been shown that 
DNA methylation outside promoters may also be crucial 
for gene regulation [25]. Clearly, this might reveal new 
aspects of NB tumorigenesis.
Finally, a new statistical framework was applied 
to identify a robust set of MSP assays of which the 
methylation scores of the samples allow accurate outcome 
prediction. Both for OS and EFS, a 58-marker signature 
with a methylation score cutoff of 25% was selected based 
on the data of MSP cohort I. Survival analyses on both 
MSP cohort I and II indicate that the signature displays 
prognostic value for OS and EFS, and is a significant 
independent predictor of OS in MSP cohort II after 
controlling for established NB risk factors. All newly 
discovered individual prognostic methylation biomarkers 
are part of the signature and further inspection of the 
other assays included in the signature shows biomarkers 
previously described in other tumor types, as well as 
genes previously linked to NB, such as NAV2, which 
functions in axonal elongation and is required for all-
trans retinoic acid to induce neurite outgrowth in human 
NB cells [31]. Also in this regard, the present study is 
unique, since combining multiple individual methylation 
assays into a single biomarker signature is not previously 
reported in NB, with the exception of testing the CpG 
island methylator phenotype (CIMP), but this assay panel 
was simply adopted from the colorectal cancer research 
field. Yet, it should be tested whether these established 
DNA methylation biomarkers can further improve the 
performance of our 58-marker signature. 
In conclusion, the applications of DNA methylation 
biomarkers in cancer management are versatile and these 
should definitely be further explored in the context of 
NB. During the past decades, many efforts have been 
made to identify prognostic DNA methylation biomarkers 
for NB, but currently no such biomarkers have made it 
to the clinic, as they lack comprehensive validation. 
In our study, we performed genome-wide methylation 
profiling of primary NB tumors using MBD sequencing 
to discover novel prognostic methylation biomarkers and 
subsequently tested top candidates in two independent 
cohorts using MSP. As such, we comprised 396 patients 
in total, which greatly increases the validity of the study 
and makes it the largest DNA methylation biomarker 
study in NB to date. We robustly identified several novel 
individual biomarkers for OS and EFS, and could develop 
a prognostic 58-marker signature of which a methylation 
score cutoff of 25% allows accurate outcome prediction 
in the total patient cohorts. Furthermore, on the validation 
cohort, this signature was an independent predictor of 
OS after controlling for known NB risk factors, clearly 
indicating its clinical relevance. As such, this study forms a 
solid basis for further investigation of our biomarkers and 
signature in NB subgroups which could not be robustly 
examined in our cohorts (low-risk non-survivors and 
more homogeneous high-risk subgroups). Ideally, also the 
integration with other DNA methylation biomarkers and 
-omic data should be further explored to fully optimize the 
assessment of NB prognosis and appropriate stratification 
of patient treatment. 
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MAterIAls And Methods
neuroblastoma cell lines and primary tumors 
In total, 437 primary NB tumor samples were used 
to establish four independent sample cohorts: MBD 
cohort I (n = 42), MBD cohort II (n = 45), MSP cohort 
I (n = 148) and MSP cohort II (n = 202). Also 19 NB 
cell lines (Supplemental Table 3) were included in the 
study. All primary tumor samples were assigned to one 
of three previously defined [10] risk groups based on 
NB risk parameters (INSS stage, MYCN amplification 
status and age of the patient at diagnosis) and disease 
outcome: (1) high-risk patients that died of disease (HR-
DOD), (2) high-risk survivors (HR-SURV), or (3) low-
risk survivors (LR-SURV). Samples were collected at the 
Centre Léon Bérard (n = 125, Lyon, France), the Hospital 
Clínico Universitario (n = 86; Valencia, Spain), the Ghent 
University Hospital (n = 80; Ghent, Belgium), the Sydney 
Children’s Hospital (n = 48; Sydney, Australia), the Institut 
Curie (n = 37, Paris, France), the Children’s Cancer and 
Leukemia Group (n = 29, Leicester, UK), the Our Lady’s 
Children’s Hospital Dublin (n = 13; Dublin, Ireland), the 
University Hospital Brno (n = 11, Brno, Czech Republic) 
and the University Children’s Hospital Essen (n = 8; 
Essen, Germany). Detailed clinical characteristics of the 
patients and a summary across the different subcohorts are 
given in Supplemental Table 1. The study was approved 
by the ethical committee of the Ghent University Hospital 
(approval number: B67020109912). 
Methyl-cpG-binding domain sequencing
DNA fragmentation and MBD-based capturing 
of 42 (MBD cohort I) and 45 (MBD cohort II) samples 
were performed as described in [32] and Decock et al., in 
preparation. Briefly, 200-500 ng sheared DNA was used 
to enrich for methylated fragments using the MethylCap 
kit (MBD from MeCP2; Diagenode). For each captured 
fraction of the samples of MBD cohort I, DNA library 
preparation was performed using the NEBNext DNA 
Library Prep Master Mix Set for Illumina (New England 
Biolabs) in combination with the Multiplexing Sample 
Preparation Oligonucleotide Kit (Illumina) for paired-end 
adapter ligation. For the input and enriched fractions of 
the samples of MBD cohort II, library preparation was 
automated on an Apollo 324 Next Generation Sequencing 
Library Preparation System (IntegenX), making use of the 
PrepX ILM DNA Library Kit (IntegenX) in combination 
with the Multiplexing Sample Preparation Oligonucleotide 
Kit. Paired-end sequencing was performed on a Illumina 
GAIIx (MBD cohort I; PE 2 x 45 bp) and HiSeq2000 
(MBD cohort II; PE 2 x 51 bp). 
Methylation-specific PCR
Experimental MSP conditions and methylation 
calling were done as previously described [10] and are 
shown in Figure 1. Here, 78 technically validated MSP 
primer pairs (and the methylation-independent ACTB 
control assay; Supplemental Table 2) were tested on 
amplified bisulfite-treated DNA from 19 NB cell lines 
and two independent cohorts of 148 (MSP cohort I) and 
202 (MSP cohort II) patients, selected from the previously 
defined prognostic patient groups. 
bioinformatics and statistical analyses
Methyl-cpG-binding domain sequencing 
Raw MBD sequencing data were demultiplexed and 
converted to FASTQ files. Quality control was performed 
by FastQC, followed by paired-end read mapping to the 
human reference genome (hg19) using Bowtie2 [33] and 
SAMtools [34]. PCR duplicates were marked by Picard 
and mapping quality control was done by SAMStat [35] 
and bamUtil. Peaks were called using MACS [36]. Data 
have been deposited into the Gene Expression Omnibus 
(GEO; GSE69224 and GSE69243). Count matrices for 
differential methylation analyses between the prognostic 
patient subgroups in DESeq [37] were constructed using 
the R ShortRead [38] and rtracklayer [39] packages. 
Here, for both MBD cohorts, two count datasets were 
constructed. The first one represents a table that reports 
for each MBD-enriched sample the number of mapped 
reads that are assigned to the promoter region (-1500 bp 
to +500 bp around transcription start site (TSS)) of the 
different Ensembl Transcripts (release 68), and the second 
one to 5 kb genomic windows (2.5 kb overlapping moving 
windows). Hierarchical clustering was performed using 
the R gplots and RColorBrewer packages.
Methylation-specific PCR 
For survival analyses on the MSP data, the Kaplan-
Meier method was used to estimate overall and event-
free survival (OS and EFS) probabilities, and survival 
functions were compared with the log-rank test (R survival 
package). OS time was defined as the time between 
diagnosis and disease-related death or last follow-up. EFS 
time is the time between diagnosis and first occurrence of 
relapse, progression or death of disease, or last follow-up. 
P-values < 0.05 were considered statistically significant. 
All individual assays were tested, as well as a multimarker 
signature that was established on MSP cohort I using a 
new statistical framework (Figure 2 and Cannoodt et al., 
in preparation). This framework involves three major 
steps: (1) the construction of signatures, (2) the evaluation 
of the performance and robustness of each constructed 
signature, and (3) the signature selection. The construction 
of signatures (step 1) is based on the performance of the 
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individual assays, which is evaluated by determining the 
following statistical metrics: sensitivity (true positive 
rate (TPR)), specificity (true negative rate (TNR)) and 
balanced accuracy (BAC). Each of these metrics was 
subsequently used to rank the assays (from highest to 
lowest value) and a cutoff, defined by percentiles of the 
ranked list (from 0% to 100% with 5% increment; 21 
possible cutoffs), was applied to select a specific assay 
set. Then, the methylation score (i.e. the percentage of 
methylated assays) for each of the samples is calculated 
and used to rank the samples (from lowest to highest 
value). Again, a percentage cutoff is applied on the ranked 
list, which allows making risk predictions for each sample. 
Samples with a methylation score above the cutoff have 
a high risk. Samples with a methylation score below 
the cutoff have a low risk. Given the number of tested 
metrics to evaluate the individual assay performance (3 
possibilities), the number of possible cutoffs to select a 
specific assay set (21 possibilities), and the number of 
possible methylation score cutoffs (21 possibilities), 1323 
signatures were constructed and further evaluated on their 
performance and robustness (step 2). The performance of 
the constructed signatures was examined by determining 
the BAC, as well as a score that reflects how well the 
percentage of predicted samples with an event equals the 
true percentage of samples with an event (score of % event 
samples in Figure 2). The robustness of the constructed 
signatures was tested by performing 100 bootstraps, 
creating a subcohort containing half of the samples. For 
each of these 100 subcohorts, signatures were constructed 
as described above and for each combination of parameters 
the Jaccard similarity index [40] between the selected 
assay set on the entire cohort and the bootstrap cohort was 
computed. The robustness of the signature is then reflected 
in the mean Jaccard similarity of the 100 bootstraps (R 
caret package). In order to select a final signature (step 
3), the performance and robustness metrics are combined 
in a weighted harmonic mean, and the signature with the 
highest value is retained. Also power analyses (SAS Power 
and Sample Size), and univariable and multivariable 
logistic regression analyses (R survival package) were 
performed. Included factors in the multivariable analyses 
are: the MYCN amplification status (MYCN amplified 
versus non-amplified as reference), age of the patient at 
diagnosis (> 18 months versus ≤ 18 months as reference 
[41]), INSS stage (stage 4 versus not stage 4 as reference) 
and the signature prediction (methylation high-risk 
versus methylation low-risk as reference). Associations 
between the prognostic DNA methylation biomarkers and 
established NB risk factors (MYCN amplification, age at 
diagnosis (cutoff of 12 months and 18 months) and INSS 
stage) were determined using Fisher’s exact test.
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